Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01530269 · ClinicalTrials.gov registry record · Phase 2
C11-Sodium Acetate PET/CT Imaging for Metastatic Disease in Intermediate-to-high Risk Prostate Adenocarcinoma
A Phase 2 study of Prostate Cancer and Prostate Adenocarcinoma, sponsored by Phoenix Molecular Imaging.
- Completed
- Registry status
- Phase 2
- Development phase
- 300
- Enrollment target
- 1
- Study location
NCT01530269 is a Phase 2 study of Prostate Cancer and Prostate Adenocarcinoma that has completed, run by Phoenix Molecular Imaging. The registered enrollment target is 300 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (51% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01530269, a Phase 2 study of Prostate Cancer and Prostate Adenocarcinoma, has completed, sponsored by Phoenix Molecular Imaging.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 300 participants
- Enrollment target
- 1
- Study location
Study Summary
Positron emission tomography using carbon-11 acetate (AC-PET) may help find local or distant metastases from prostate cancer. This clinical trial is studying how this imaging test may help influence the choice and extent of initial treatments, and subsequent treatments.
Conditions Studied
Interventions
- DRUG C11-Sodium Acetate
Study Locations (1)
Arizona
- Phoenix Molecular Imaging - Phoenix
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2012-04 |
| Est. Completion | 2019-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01530269
The ClinicalTrials.gov registry entry for NCT01530269 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (51% lower). The listed sponsor is Phoenix Molecular Imaging, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which C11-Sodium Acetate is the first listed.
NCT01530269 reports 1 study location spanning 1 distinct geographic area - top geographies include Arizona.
Frequently Asked Questions
What is clinical trial NCT01530269 about?
NCT01530269 is a clinical study titled "C11-Sodium Acetate PET/CT Imaging for Metastatic Disease in Intermediate-to-high Risk Prostate Adenocarcinoma". Positron emission tomography using carbon-11 acetate (AC-PET) may help find local or distant metastases from prostate cancer. This clinical trial is studying how this imaging test may help influence the choice and extent of initial treatments, and subsequent treatments.
What is the current status of trial NCT01530269?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 300 participants. The study started on 2012-04. Estimated completion is 2019-01.
What conditions does trial NCT01530269 study?
This clinical trial studies the following conditions: Prostate Cancer, Prostate Adenocarcinoma.
What interventions are being tested in trial NCT01530269?
The interventions under investigation include: C11-Sodium Acetate (DRUG).
Who is sponsoring clinical trial NCT01530269?
This trial is sponsored by Phoenix Molecular Imaging, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01530269 being conducted?
This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer
RECRUITING · Phase 2
-
Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer
RECRUITING · Phase 2
-
Post-prostatectomy Radiation Therapy--Moderate Versus Ultra-hypofractionated (Also Known as Stereotactic Body Radiation Therapy [SBRT])
RECRUITING · Phase 2
-
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
RECRUITING · Phase 2
-
Utility of Hyperpolarized 13C-pyruvate Metabolic Magnetic Resonance Imaging
RECRUITING · Phase 2
-
High Intensity Focused Ultrasound in Prostate Cancer
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.